文章基本信息

标题：Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4
本地全文：下载
作者：Nobutaka Masuoka ; Chitose Yoshimine ; Marie Hori 等
期刊名称：Nutrients
电子版ISSN：2072-6643
出版年度：2019
卷号：11
期号：7
页码：1626-1638
DOI：10.3390/nu11071626
出版社：MDPI Publishing
摘要：Background: Oral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI. Methods: A randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery. Results: The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer’s Disease Assessment Scale (ADAS). When APOE4 positive (APOE4 ( )) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 ( ) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026). Conclusions: The present study might suggest that protective effects against cognitive decline in APOE4 ( ) MCI subjects exist.
关键词：Alzheimer’s disease; cognitive functions; anserine and carnosine; randomized controlled trial (RCT); mild cognitive impairment (MCI); APOE4 Alzheimer’s disease ; cognitive functions ; anserine and carnosine ; randomized controlled trial (RCT) ; mild cognitive impairment (MCI) ; APOE4